The Changing Landscape of Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation: Use of the Direct Thrombin Inhibitors

Cindy Neunert, Meera Chitlur, Cornelia Heleen van Ommen

Research output: Contribution to journalReview articlepeer-review

Abstract

Bleeding and thrombosis frequently occur in pediatric patients with extracorporeal membrane oxygenation (ECMO) therapy. Until now, most patients are anticoagulated with unfractionated heparin (UFH). However, heparin has many disadvantages, such as binding to other plasma proteins and endothelial cells in addition to antithrombin, causing an unpredictable response, challenging monitoring, development of heparin resistance, and risk of heparin-induced thrombocytopenia (HIT). Direct thrombin inhibitors (DTIs), such as bivalirudin and argatroban, might be a good alternative. This review will discuss the use of both UFH and DTIs in pediatric patients with ECMO therapy.

Original languageEnglish
Article number887199
JournalFrontiers in Medicine
Volume9
DOIs
StatePublished - Jul 6 2022

Keywords

  • anticoagulation
  • argatroban
  • bivalirudin
  • extracorporeal membrane oxygenation
  • pediatric
  • unfractionated heparin

Fingerprint

Dive into the research topics of 'The Changing Landscape of Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation: Use of the Direct Thrombin Inhibitors'. Together they form a unique fingerprint.

Cite this